Pura Vida Investments’s Viridian Therapeutics VRDN Stock Holding History

Pura Vida Investments’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-35,003	Closed	-$1.02M	–	175
2022 Q4	$1.02M	Sell	35,003 -40,000	-53%	-$922K	0.05%	145
2022 Q3	$1.54M	Sell	75,003 -30,457	-29%	-$548K	0.09%	145
2022 Q2	$1.22M	Hold	105,460	–	–	0.07%	158
2022 Q1	$1.95M	Buy	105,460 +600	+0.6%	+$11.5K	0.06%	162
2021 Q4	$2.07M	Buy	104,860 +46,764	+80%	+$871K	0.08%	147
2021 Q3	$956K	Buy	+58,096	New	+$852K	0.03%	222

Other funds holding VRDN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Pura Vida Investments's VRDN Position: Q1 2023 in Review

Pura Vida Investments sold out of Viridian Therapeutics (VRDN) in Q1 2023, closing a stake of 35,003 shares — an estimated $1.02M sold.

Pura Vida Investments first reported a position in VRDN in Q3 2021 and held it in 6 quarters. The position peaked at $2.07M in Q4 2021. 135 funds tracked by Wall St. Rank hold VRDN as of Q1 2023.

Pura Vida Investments reported no remaining Viridian Therapeutics position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 35,003 Viridian Therapeutics shares in Q1 2023, an estimated $1.02M.
Pura Vida Investments first reported a position in Viridian Therapeutics in Q3 2021 and held it in 6 quarters.
Pura Vida Investments's Viridian Therapeutics position peaked at $2.07M in Q4 2021.
135 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.